{
    "id": "5c900779ecadf2e73f000001",
    "question": "Can antisense threapy be used for Huntington's disease?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and identify any information related to the use of antisense therapy for Huntington's disease. First, we need to understand what antisense therapy is. Antisense therapy involves using oligonucleotides (e.g., antisense oligonucleotides, siRNAs) to target specific RNA sequences and prevent their translation into proteins. In the context of Huntington's disease, the disease is caused by an expansion of CAG repeats in the huntingtin gene, leading to toxic protein production. Therefore, targeting the huntingtin mRNA could potentially prevent or slow down the disease progression. Next, we need to look for documents that mention the use of antisense therapy for Huntington's disease. Document [4] (Title: Neurology_Adams) mentions that novel therapeutic agents in the form of antisense oligonucleotides are currently being tested for Huntington's disease. Document [20] (Title: Psichiatry_DSM-5) also mentions that antisense oligonucleotides are being investigated as a potential treatment for Huntington's disease. Finally, Document [22] (Title: Neurology_Adams) mentions that nusinersen, an antisense oligonucleotide, has been shown to be effective in treating spinal muscular atrophy, which is a different disease but also involves a genetic defect that can be treated with antisense therapy. Based on these findings, it appears that antisense therapy may be a viable option for treating Huntington's disease.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "Neurology_Adams_8586",
            "title": "Neurology_Adams",
            "content": "is an inhibitor of vesicular monoamine oxidase transporter 2 (VMAT2) and has been validated in a controlled study (Huntington Study Group)\u2014suppress the chorea to some degree, but their side effects (drowsiness, akathisia, and tardive dyskinesia) usually outweigh their desired effects. Deutetrabenazine is a newer VMAT2 inhibitor, which has been approved for use in HD. Both tetrabenazine and deutrabenazine are contraindicated in patients with active suicidality or inadequately treated depression. The juvenile (rigid) form of the disease is probably best treated with antiparkinsonian drugs. Preliminary studies of the transplantation of fetal ganglionic tissue into the striatum have achieved mixed results. The psychologic and social consequences of the disease require supportive therapy, and genetic counseling is essential. Antidepression drugs are widely implemented because of the high incidence of depression and suicidality but their efficacy is not clear. Huntington disease pursues a"
        },
        {
            "id": "Psichiatry_DSM-5_3057",
            "title": "Psichiatry_DSM-5",
            "content": "Genetic and physiological. The genetic basis of Huntington\u2019s disease is a fully penetrant autosomal dominant expansion of the CAG trincleotide, often called a CAG repeat in the huntingtin gene. A repeat length of 36 or more is invariably associated with Huntington\u2019s disease, with longer repeat lengths associated with early age at onset. A CAG repeat length of 36 or more is invariably associated with Huntington\u2019s disease."
        },
        {
            "id": "InternalMed_Harrison_29700",
            "title": "InternalMed_Harrison",
            "content": "Interestingly, in experimental models of Huntington\u2019s disease and cerebellar degeneration, protein aggregates are not well correlated with neuronal death and may be protective. A substantial body of evidence suggests that the mutant proteins with polyglutamine expansions in these diseases bind to transcription factors and that this contributes to disease pathogenesis. In Huntington\u2019s disease, there is dysfunction of the transcriptional co-regulator, PGC-1\u03b1, a key regulator of mitochondrial biogenesis. There is evidence that impaired function of PGC-1\u03b1 is also important in both Parkinson\u2019s disease and AD, making it an attractive target for treatments. Agents that upregulate gene transcription are neuroprotective in animal models of these diseases. A number of compounds have been developed to block \u03b2-amyloid production and/or aggregation, and these agents are being studied in early clinical trials in humans. Another approach under investigation is immunotherapy with antibodies that bind"
        },
        {
            "id": "Pharmacology_Katzung_3923",
            "title": "Pharmacology_Katzung",
            "content": "Mipomersen is an antisense oligonucleotide that targets apo B-100, mainly in the liver. It is important to note that the apo B-100 gene is also transcribed in the retina and in cardiomyocytes. Subcutaneous injections of mipomersen reduce levels of LDL and Lp(a). Mild to moderate injection site reactions and flu-like symptoms can occur. The drug is available only for use in homozygous familial hypercholesterolemia through a restricted (REMS) program."
        },
        {
            "id": "Neurology_Adams_8588",
            "title": "Neurology_Adams",
            "content": "Novel therapeutic agents in the form of antisense oligonucleotides are currently being tested. These agents are introduced intrathecally and bind to huntingtin mRNA in the central nervous system. In early stage in-human safety and tolerability studies lead to dose-dependent reduction in huntingtin mRNA and protein. This approach is comparable to what has been accomplished in spinal muscular atrophy (discussed later in this chapter)."
        },
        {
            "id": "Obstentrics_Williams_8408",
            "title": "Obstentrics_Williams",
            "content": "Prevention of relapses postpartum is aforded by treatment with intravenous immunoglobulin (I I G) , given in a dose of 0.4 g/kg daily for 5 days during weeks 1, 6, and 12 (Argyriou, 2008). his adult-onset neurodegenerative disease stems from an autosomal dominant expanded CAG trinucleotide repeat within the Huntington gene on chromosome 4. It is characterized by choreoathetotic movements, progressive dementia, and psychiatric manifestations. Because the mean age of onset is 40 years, Huntington disease rarely complicates pregnancy. Prenatal diagnosis is discussed in Chapter 14 (p. 288). Prenatal screening is controversial, and because this usually is a late-onset adult disease, extensive counseling is important (Schulman, 2015)."
        },
        {
            "id": "InternalMed_Harrison_29683",
            "title": "InternalMed_Harrison",
            "content": "Huntington\u2019s disease, in which using low-dose memantine to selectively block the extrasynaptic receptors is beneficial."
        },
        {
            "id": "InternalMed_Harrison_30570",
            "title": "InternalMed_Harrison",
            "content": "No treatment arrests the underlying pathologic process in ALS. The drug riluzole (100 mg/d) was approved for ALS because it produces a modest lengthening of survival. In one trial, the survival rate at 18 months with riluzole was similar to placebo at 15 months. The mechanism of this effect is not known with certainty; riluzole may reduce excitotoxicity by diminishing glutamate release. Riluzole is generally well tolerated; nausea, dizziness, weight loss, and elevated liver enzymes occur occasionally. Pathophysiologic studies of mutant SOD1\u2013related ALS in mice have disclosed diverse targets for therapy; consequently, multiple therapies are presently in clinical trials for ALS including experimental trials of small molecules, mesenchymal stem cells, and immunosuppression. Interventions such as antisense oligonucleotides (ASO) that diminish expression of mutant SOD1 protein prolong survival in transgenic ALS mice and rats and are also nearing trial now for SOD1-mediated ALS."
        },
        {
            "id": "InternalMed_Harrison_30426",
            "title": "InternalMed_Harrison",
            "content": "In anticipation of developing neuroprotective therapies, there has been an intensive effort to define the premanifest stage of HD. Subtle motor impairment, cognitive alterations, and imaging changes can be detected in at-risk individuals who later go on to develop the manifest form of the disease. Defining the rate of progression of these features is paramount for future studies of putative disease-modifying therapies. HD is caused by an increase in the number of polyglutamine (CAG) repeats (>40) in the coding sequence of the huntingtin gene located on FIGURE 449-8 Huntington\u2019s disease. A. Coronal fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging shows enlargement of the lateral ventricles reflecting typical atrophy (arrows). B. Axial FLAIR image demonstrates abnormal high signal in the caudate and putamen (arrows)."
        },
        {
            "id": "InternalMed_Harrison_30430",
            "title": "InternalMed_Harrison",
            "content": "antidepressant and antianxiety drugs and monitored for mania and suicidal ideations. Psychosis can be treated with atypical anti-psychotics such as clozapine (50\u2013600 mg/d), quetiapine (50\u2013600 mg/d), and risperidone (2\u20138 mg/d). There is no adequate treatment for the cognitive or motor decline. A neuroprotective therapy that slows or stops disease progression is the major unmet medical need in HD. Drugs that enhance mitochondrial function and increase the clearance of defective mitochondria are being tested as possible disease-modifying therapies. Antiglutamate agents, dopamine stabilizers, caspase inhibitors, neurotrophic factors, and transplantation of fetal striatal cells are areas of active research, but none has as yet been demonstrated to have a beneficial effect in HD. The potential to use transcriptional blockade of the mutant huntingtin gene with small interfering RNAs (siRNAs) is an exciting area currently being explored."
        },
        {
            "id": "Pathology_Robbins_1644",
            "title": "Pathology_Robbins",
            "content": "Perhaps sequestration of these proteins at abnormal locations leads to events that are toxic to the cell. As noted, earlier many other neurodegenerative diseases related to trinucleotide repeat expansions are recognized. Some general principles follow: In all cases, gene functions are altered by an expansion of the repeats, but the precise threshold at which premutations are converted to full mutations differs with each disorder. Whereas the expansion in fragile X syndrome occurs during oogenesis, in other disorders such as Huntington disease, premutations are converted to full mutations during spermatogenesis. The expansion may involve any part of the gene, and the range of possibilities can be divided into two broad categories: those that affect untranslated regions (as in fragile X syndrome) and those that affect coding regions (as in Huntington disease) ("
        },
        {
            "id": "Pharmacology_Katzung_3925",
            "title": "Pharmacology_Katzung",
            "content": "who have familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional reduction of LDL. They are given with diet and maximal tolerated statin and/or ezetimibe. Development of small molecules and antisense oligonucleotides to inhibit PCSK9 is underway. Studies of PCSK9 inhibition should be approached with caution because of its established role in normal cell biology. These agents are very expensive."
        },
        {
            "id": "Neurology_Adams_8843",
            "title": "Neurology_Adams",
            "content": "As with Huntington chorea (where the expanded polyglutamine sequence is in the protein huntingtin), this disease is inherited as an autosomal dominant trait and shows an inverse correlation between the age of onset and the size of the gene expansion (anticipation). When chorea predominates early in the illness, there may be difficulty distinguishing DRPLA from Huntington disease. The pathology has been summarized by Iizuka and colleagues. The diagnosis is confirmed by sequencing of the affected gene."
        },
        {
            "id": "InternalMed_Harrison_4887",
            "title": "InternalMed_Harrison",
            "content": "nucleotiDe rePeat exPansion DisorDers Several diseases are associated with an increase in the number of nucleotide repeats above a certain threshold (Table 82-4). The repeats are sometimes located within the coding region of the genes, as in Huntington\u2019s disease or the X-linked form of spinal and bulbar muscular atrophy (SBMA; Kennedy\u2019s syndrome). In other instances, the repeats probably alter gene regulatory sequences. If an expansion is present, the DNA fragment is unstable and tends to expand further during cell division. The length of the nucleotide repeat often correlates with the severity of the disease. When repeat length increases from one generation to the next, disease manifestations may worsen or be observed at an earlier age; this phenomenon is referred to as anticipation. In Huntington\u2019s disease, for example, there is a correlation between age of onset and length of the triplet codon expansion (Chap. 444e). Anticipation has also been documented in other diseases caused by"
        },
        {
            "id": "Neurology_Adams_11438",
            "title": "Neurology_Adams",
            "content": "With another remarkable approach, it has been possible to cause the skipping of selected exons during splicing of pre-mRNA and to correct the open reading frame in mutated dystrophin. For example, van Deutekom and colleagues have been able to elicit expression of normal dystrophin in the anterior tibialis at the site of injection of an antisense oligonucleotide that promotes the exon skipping. The same oligonucleotide administered subcutaneously for 5 weeks was shown by Goermans and coworkers to produce dystrophin expression and modestly improve the ability of patients to accomplish a standardized 6-min walk test."
        },
        {
            "id": "Neurology_Adams_8554",
            "title": "Neurology_Adams",
            "content": "To quote Huntington, the rule has been that \u201cWhen either or both of the parents have shown manifestations of the disease, one or more of the offspring invariably suffer of the disease, if they live to adult life. But if by any chance these children go through life without it, the thread is broken and the grandchildren and great grandchildren of the original shakers may rest assured that they are free from disease.\u201d Vessie in a review of 962 patients with Huntington chorea, found only 5 who had descended from unaffected parents. Possibly, in these 5 patients, a parent had the trait, in very mild form, or parentage was in question, because spontaneous mutations are rare."
        },
        {
            "id": "Neurology_Adams_8558",
            "title": "Neurology_Adams",
            "content": "coding for glutamine. Individuals with 35 to 39 triplets may eventually manifest the disease but it tends to be late in onset and mild in degree, or limited to the below-mentioned \u201csenile chorea.\u201d Those with more than 42 repeats almost invariably acquire the signs of disease if they live long enough. The rare alternative mutation, termed HDL2 (Huntington disease-like-2), is associated with CATCG repeat expansion of the juntophilin-3 gene, but it is so infrequent that few clinicians will encounter it (Margolis et al)."
        },
        {
            "id": "InternalMed_Harrison_5445",
            "title": "InternalMed_Harrison",
            "content": "This chapter has focused on gene addition therapy, in which a normal gene is transferred to a target tissue to drive expression of a gene product with therapeutic effects. Another powerful technique under development is genome editing, in which a mutation is corrected in situ, generating a wild-type copy under the control of the endogenous regulatory signals. This approach makes use of novel reagents including zinc finger nucleases, TALENs and CRISPR, which introduce double-stranded breaks into the DNA near the site of the mutation and then rely on a donated repair sequence and cellular mechanisms for repair of double-strand breaks to reconstitute a functioning gene. Another strategy recently introduced into clinical trials is the use of siRNAs or short hairpin RNAs as transgenes to knock down expression of deleterious genes (e.g., mutant huntingtin in Huntington\u2019s disease or genes of the hepatitis C genome in infected individuals)."
        },
        {
            "id": "Psichiatry_DSM-5_3053",
            "title": "Psichiatry_DSM-5",
            "content": "CAG trinucleotide repeat expansion in the HTT gene, located on chromosome 4. Depression, irritability, anxiety, obsessive-compulsive symptoms, and apathy are fre- quently, and psychosis more rarely, associated with Huntington\u2019s disease and often pre- cede the onset of motor symptoms. Neurocognitive deficits are an eventual outcome of Huntington\u2019s disease; the worldwide prevalence is estimated to be 2.7 per 100,000. The prevalence of Huntington\u2019s disease in North America, Europe, and Australia is 5.7 per 100,000, with a much lower prevalence of 0.40 per 100,000 in Asia."
        },
        {
            "id": "Neurology_Adams_8587",
            "title": "Neurology_Adams",
            "content": "genetic counseling is essential. Antidepression drugs are widely implemented because of the high incidence of depression and suicidality but their efficacy is not clear. Huntington disease pursues a steadily progressive course and death occurs as mentioned, on average 15 to 20 years after onset, sometimes much earlier or later."
        },
        {
            "id": "Psichiatry_DSM-5_3052",
            "title": "Psichiatry_DSM-5",
            "content": "(Note: Do not use the additional code for Huntington's disease. Behavioral disturbance cannot be coded but should still be indicated in writing.) Progressive cognitive impairment is a core feature of Huntington\u2019s disease, with early changes in executive function (i.e., processing speed, organization, and planning) rather than leam- ing and memory. Cognitive and associated behavioral changes often precede the emergence of the typical motor abnormalities of bradykinesia (i.e., slowing of voluntary movement) and chorea (i.e., involuntary jerking movements). A diagnosis of definite Huntington\u2019s dis- ease is given in the presence of unequivocal, extrapyramidal motor abnormalities in an in- dividual with either a family history of Huntington\u2019s disease or genetic testing showing a CAG trinucleotide repeat expansion in the HTT gene, located on chromosome 4."
        },
        {
            "id": "Psichiatry_DSM-5_3061",
            "title": "Psichiatry_DSM-5",
            "content": "Other mental disorders. Early symptoms of Huntington\u2019s disease may include instabil- ity of mood, irritability, or compulsive behaviors that may suggest another mental disor- der. However, genetic testing or the development of motor symptoms will distinguish the presence of Huntington\u2019s disease. Other neurocognitive disorders. The early symptoms of Huntington\u2019s disease, particu- larly symptoms of executive dysfunction and impaired psychomotor speed, may resemble other neurocognitive disorders (NCDs), such as major or mild vascular NCD. Major or Mild Neurocognitive Disorder Due to Another Medical Condition 641 Other movement disorders. Huntington\u2019s disease must also be differentiated from other disorders or conditions associated with chorea, such as Wilson\u2019s disease, drug-induced tardive dyskinesia, Sydenham\u2019s chorea, systemic lupus erythematosus, or senile chorea."
        },
        {
            "id": "Neurology_Adams_8929",
            "title": "Neurology_Adams",
            "content": "Treatment Two novel treatments have been remarkable developments in this otherwise dismal field. One, nusinersen, is an antisense oligonucleotide that modifies splicing of SMN2 to result in increased production of SMN protein in motor neurons and compensate for the mutated SMN1 (Finkel et al). It is delivered by repeated intrathecal injection. It was shown to be effective in later onset SMA (types 2 and 3) as noted below. The second, is gene therapy with an adeno-associated viral vector containing SMN1, delivered as a single intravenous injection (Mendell et al). This has induced SMN expression. Both of these have been tested in small numbers of patients and in some cases, against historical controls."
        },
        {
            "id": "InternalMed_Harrison_28273",
            "title": "InternalMed_Harrison",
            "content": "Specialized druGS for HomozyGouS fH Two \u201corphan\u201d drugs are approved specifically for the management of homozygous FH. They include a small-molecule inhibitor of MTP, called lomitapide, and an antisense oligonucleotide against apoB, called mipomersen. These drugs reduce VLDL production and LDL-C levels in homozygous FH patients. Due to their mechanism of action, each drug causes an increase in hepatic fat, the long-term consequences of which are unknown. In addition, lomitapide is associated with gastrointestinal-related side effects, and mipomersen is associated with skin reactions and flu-like symptoms."
        },
        {
            "id": "Pharmacology_Katzung_3093",
            "title": "Pharmacology_Katzung",
            "content": "Huster D: Wilson disease. Best Pract Res Clin Gastroenterol 2010;24:531. Jankovic J: Medical treatment of dystonia. Mov Disord 2013;28:1001. Kalia LV, Kalia SK, Lang AE: Disease-modifying strategies for Parkinson\u2019s disease. Mov Disord 2015;30:1442. Kimber TE: An update on Tourette syndrome. Curr Neurol Neurosci Rep 2010;10:286. Kordower JH et al: Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Mov Disord 2008;23:2303. LeWitt PA et al: AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309. Lorincz MT: Neurologic Wilson\u2019s disease. Ann N Y Acad Sci 2010;1184:173. Lyons KE, Pahwa R: Outcomes of rotigotine clinical trials: Effects on motor and nonmotor symptoms of Parkinson\u2019s disease. Neurol Clin 2013;31(3 Suppl):S51. Olanow CW et al: A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med 2009;361:1268."
        },
        {
            "id": "Neurology_Adams_8581",
            "title": "Neurology_Adams",
            "content": "Chorea in early adult life always raises the question of a late form of Sydenham chorea, of lupus erythematosus with antiphospholipid antibodies, or of cocaine use, but neither familial occurrence nor mental deterioration is part of these processes. A \u201cbenign inherited chorea,\u201d transmitted as an autosomal dominant trait without prolongation of a triplet sequence, has been traced to chromosome 14q. It is differentiated from Huntington disease by onset before age 5 years, progressing little, and having no associated mental deterioration (Breedveld et al). Other progressive neurologic disorders inherited as autosomal dominant traits and beginning in adolescence or adult life (e.g., polymyoclonus with or without ataxia, acanthocytosis with progressive chorea, and dentatorubropallidoluysian degeneration) can closely mimic Huntington disease, as described further on; sometimes only the genetic and pathologic findings settle the matter. A midlife progressive chorea without dementia (after"
        },
        {
            "id": "InternalMed_Harrison_5407",
            "title": "InternalMed_Harrison",
            "content": "Gene transfer strategies for genetic disease generally involve gene addition therapy, an approach characterized by transfer of the missing gene to a physiologically relevant target cell. However, other strategies are possible, including supplying a gene that achieves a similar biologic effect through an alternative pathway (e.g., factor VIIa for hemophilia A); supplying an antisense oligonucleotide to splice out a mutant exon if the sequence is not critical to the function of the protein (as has been done with the dystrophin gene in Duchenne\u2019s muscular dystrophy); or downregulating a harmful effect through a small interfering RNA (siRNA). Two distinct strategies are used to achieve long-term gene expression: one is to transduce stem cells with an integrating vector, so that all progeny cells will carry the donated gene; and the other is to transduce long-lived cells, such as skeletal muscle or neurons. In the case of long-lived cells, integration into the target cell genome is"
        },
        {
            "id": "InternalMed_Harrison_30429",
            "title": "InternalMed_Harrison",
            "content": "Although the gene for HD was identified more than two decades ago, there is still no disease-modifying therapy for this disorder. Current treatment involves a multidisciplinary approach, with medical, neuropsychiatric, social, and genetic counseling for patients and their families. Dopamine-blocking agents may control the choreatic movements. Tetrabenazine (a presynaptic dopamine depleting agent) has been approved for the treatment of chorea in the United States, but can cause secondary parkinsonism. Neuroleptics are generally not recommended because of their potential to induce other more troubling movement disorders and because HD chorea tends to be self-limited and is usually not disabling. Depression and anxiety can be greater problems, and patients should be treated with appropriate antidepressant and antianxiety drugs and monitored for mania and suicidal ideations. Psychosis can be treated with atypical anti-psychotics such as clozapine (50\u2013600 mg/d), quetiapine (50\u2013600 mg/d),"
        },
        {
            "id": "Neurology_Adams_8932",
            "title": "Neurology_Adams",
            "content": "The disease progresses very slowly, and some patients survive to old age without serious disability. In general, the earlier the onset, the less favorable the prognosis; however, even the most severely affected patients retain the ability to walk for at least 10 years after the onset. Admittedly, it is difficult to make a sharp distinction between these cases of Wohlfart-Kugelberg-Welander disease and certain milder instances of Werdnig-Hoffmann disease with onset in late infancy and early childhood and prolonged survival (Byers and Banker). A form that is intermediate between the severe Werdnig-Hoffman type and the milder Wohlfart- Kugelberg-Welander is termed Dubowitz syndrome and designated SMA 2. It is in this disorder that the intrathecal administration of nusinersen, the antisense oligonucleotide referenced above, has been shown to be effective (Mercuri et al). Kennedy Disease (X-Linked Bulbospinal Muscular Atrophy, AR Mutation)"
        },
        {
            "id": "Psichiatry_DSM-5_3054",
            "title": "Psichiatry_DSM-5",
            "content": "North America, Europe, and Australia is 5.7 per 100,000, with a much lower prevalence of 0.40 per 100,000 in Asia. The average age at diagnosis of Huntington\u2019s disease is approximately 40 years, although this varies widely. Age at onset is inversely correlated with CAG expansion length. Juve- nile Huntington\u2019s disease (onset before age 20) may present more commonly with brady- kinesia, dystonia, and rigidity than with the choreic movements characteristic of the adult- onset disorder. The disease is gradually progressive, with median survival approximately 15 years after motor symptom diagnosis."
        },
        {
            "id": "Neurology_Adams_8979",
            "title": "Neurology_Adams",
            "content": "Bates G: Huntingtin aggregation and toxicity in Huntington\u2019s disease. Lancet 361:1642, 2003. Beal MF, Richardson EP Jr: Primary lateral sclerosis: A case report. Arch Neurol 38:630, 1981. Behr C: Die komplizierte, hereditar-familiare Optikusatrophie des Kindesalters: Ein bisher nicht beschriebener Symptomkomplex. Klin Monatsbl Augenheilkd 47(Pt 2):138, 1909. Bejjani B, Damier P, Arnulf I, et al: Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 340:1476, 1999. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group. N Engl J Med 330:585, 1994. Berg D, Postuma RB, Bloem B, et al: Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson\u2019s disease. Mov Disord 29:454, 2014. Bharucha NE, Bharucha EP, Bhabha SR: Machado-Joseph-Azorean disease in India. Arch Neurol 43:142, 1986."
        },
        {
            "id": "Pharmacology_Katzung_14",
            "title": "Pharmacology_Katzung",
            "content": "Pharmacogenomics\u2014the relation of the individual\u2019s genetic makeup to his or her response to specific drugs\u2014is becoming an important part of therapeutics (see Chapter 5). Decoding of the genomes of many species\u2014from bacteria to humans\u2014has led to the recognition of unsuspected relationships between receptor families and the ways that receptor proteins have evolved. Discovery that small segments of RNA can interfere with protein synthesis with extreme selectivity has led to investigation of small interfering RNAs (siRNAs) and micro-RNAs (miRNAs) as therapeutic agents. Similarly, short nucleotide chains called antisense oligonucleotides (ANOs), synthesized to be complementary to natural RNA or DNA, can interfere with the readout of genes and the transcription of RNA. These intracellular targets may provide the next major wave of advances in therapeutics."
        }
    ],
    "scores": [
        0.03208727402726626,
        0.030923335785393226,
        0.026155423612224525,
        0.025932953826691967,
        0.02538857237679075,
        0.025203340992814675,
        0.024757040505072,
        0.02379731136697697,
        0.023015662607846127,
        0.02288571274763135,
        0.02227272581210094,
        0.02216248506571087,
        0.021619081020168802,
        0.021566961000735834,
        0.021129917688115438,
        0.02074396192043251,
        0.020731613695685554,
        0.019327731092436976,
        0.01745598057073467,
        0.017379679144385027,
        0.017322718561108653,
        0.01721981014055486,
        0.01711081986311344,
        0.016337285902503294,
        0.016269841269841268,
        0.016190476190476193,
        0.016133162612035852,
        0.01581814986232351,
        0.01559109080525414,
        0.015566774852746724,
        0.014984526847277267,
        0.01497189575881451
    ]
}